September 24, 2024 07:17 AM EDT

House passes reauthorization of rare pediatric voucher program

Zachary Brennan

Senior Editor

The US House of Representatives on Monday afternoon unanimously passed a wide-ranging bill via voice vote that will reauthorize the rare pediatric priority review voucher …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

House passes reauthorization of rare pediatric voucher program

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Biogen, UCB declare Phase 3 lupus win and prep a second trial, but details are scant

Updated: Gene therapy maker bluebird bio cuts costs again, lays off staff

Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near

Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year

Exclusive: Constructive Bio raises $58M for synbio work, and Nobel laureate joins board

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

House pass­es reau­tho­riza­tion of rare pe­di­atric vouch­er pro­gram

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Bio­gen, UCB de­clare Phase 3 lu­pus win and prep a sec­ond tri­al, but de­tails are scant

Up­dat­ed: Gene ther­a­py mak­er blue­bird bio cuts costs again, lays off staff

Flag­ship’s AI biotech Gen­er­ate lands $65M up­front in No­var­tis deal, as first clin­i­cal read­outs near

Clive Mean­well's new obe­si­ty biotech, Met­sera, un­veils ear­ly GLP-1 da­ta with an eye on Phase 3 next year

Ex­clu­sive: Con­struc­tive Bio rais­es $58M for syn­bio work, and No­bel lau­re­ate joins board

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

House passes reauthorization of rare pediatric voucher program

Biogen, UCB declare Phase 3 lupus win and prep a second trial, but details are scant

Updated: Gene therapy maker bluebird bio cuts costs again, lays off staff

Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near

Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year

Exclusive: Constructive Bio raises $58M for synbio work, and Nobel laureate joins board

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships